英矽智能再次向港交所提交上市申请

Core Viewpoint - Insilico Medicine, an AI drug discovery company, has submitted a new listing application to the Hong Kong Stock Exchange, with joint sponsors including Morgan Stanley, CICC, and GF Securities (Hong Kong) [1] Group 1 - Insilico Medicine is focused on AI-driven drug development [1] - The company has previously attempted to list and is now making another effort [1] - The involvement of major financial institutions as sponsors indicates strong backing for the listing [1]